<?xml version="1.0" encoding="UTF-8"?>
<p>Continued molecular remission status in the peripheral blood after therapy (at the 12-month follow-up) was significantly associated with longer PFS (33 patients; 4-year PFS 97%). By contrast, the median PFS for patients who remained MRD-positive (n=6) or who had converted to an MRD-positive status in the peripheral blood by the 12-month follow-up (n=7) was 11 and 26 months, respectively.</p>
